Utilizing high throughput virtual screening and biological test oriented strategy, our laboratory has previously developed a platform of cell permeable small molecular survivin inhibitors, which selectively and effectively reduced survivin expression level in human melanoma and prostate cancer cells, with potent anti-tumor growth efficacy as validated by a human melanoma xenograft model[25–26]. The gene discussed is BIRC5; the disease is melanoma.